JP Morgan College Planning Guide

Good Morning All,

Attached is a piece that I received from JP Morgan concerning college education funding and the many long and short term planning elements that get intertwined with higher education.

There are a lot of impactful graphics focused on the magnitude of costs and ways to quantify the value of a college degree. JPM always does a great job with these types of reports so worth reading through.

Thank You,

Pete

Peter Malone, CFA

Portfolio Manager

Direct: 617.226.0030

Fax: 617.523.8118

Crestwood Advisors

One Liberty Square

Suite 500

Boston, MA 02109

www.crestwoodadvisors.com

JPM College Planning Guide.pdf

HLMEX – Q3 2019 Commentary

HLMEX – Q3 2019 Commentary

Overview:

The Harding Loevner Emerging Markets Equity Portfolio outperformed its benchmark during the quarter and YTD. Outperformance can be mostly attributed to strong performance of high-quality stocks, as well as weighting, where HLMEX was underweight materials and overweight IT. Stock selection was also strong in IT and healthcare which helped returns.

Continue reading “HLMEX – Q3 2019 Commentary”

TJX 3Q20 Earnings Update

Current Price: $60 Price Target: Raising to $65 from $60

Position Size: 3.4% TTM Performance: 22%

TJX is up on a strong earnings report and raised guidance. They beat on revenue and EPS, with SSS up 4% vs guidance of 1-2% (which they lowered last quarter). Off-price continues to outpace the rest of retail. Management’s commentary on the call around their inventory positioning and general environment for Marmaxx was very, very positive. Full year SSS and EPS guidance increased.

Key takeaways:

· Revenue beat on same store sales of +4% vs expected +2.6%.

· Traffic was again the biggest driver of SSS. E-commerce sales are not included in SSS numbers.

· Marmaxx (their largest segment) – comp sales increased 4%, lapping a very strong 9% increase last year.

· International had the strongest SSS of +6% – they continue to take share despite the uncertainty of Brexit and a tough retail environment in Europe.

· GM were better than expected but offset by higher SG&A. Higher payroll costs and escalating freight expenses from rising home-furniture penetration are margin headwinds.

· Excellent inventory availability – specifically, mgmt talked about growing e-commerce channels being a source of inventory supply as online merchants struggle to appropriately gauge their own inventory levels – almost all the goods they’re selling on websites are imported goods with long lead times. They are trying to predict sales by category and item, but don’t have all the history that a brick and mortar retailer would have. This highlights part of TJX’s competitive advantage – their scale and centralized merchandising. The efficacy of this is reflected in high inventory turns, which allows them to be very liquid and very opportunistic w/ inventory buys. They buy in season and continuously flow merchandise to stores.

· Tariffs – Q4 guidance includes small negative impact from tariffs. Thus far, they have benefited from vendors buying in merchandise earlier due to tariffs, which has resulted in more availability for TJX. But given TJX’s high turns, they buy-in inventory on a much shorter-term basis, so they don’t have visibility yet into 2020 and the potential impact from tariffs. They do not directly source a significant amount of goods from China.

· M&A – They disclosed a $225million investment in 25% of Familia, a major (275 store) off-price apparel/home retailer in Russia that could double its store base in the next 3-5 years. They are Russia’s only major off-price retailer. TJX may take a larger stake in the future.

· Chart below demonstrates TJX’s resistance to e-commerce and economic cycles. Despite the ramp in e-commerce share of retail over the last several years, of the companies listed below TJX is nearly half of aggregate incremental spend. The companies listed below represent more than 2/3 of the ~$275B in US apparel retail sales. Additionally, in the ’08 to ’09 period they were one of few retailers that continued to grow and post positive SSS.

Continue reading “TJX 3Q20 Earnings Update”

MDT (Medtronic) 2Q FY20 earnings summary

Key Takeaways:

Current Price: $111 Price Target: $115

Position Size: 3.35% TTM Performance: +23%

Medtronic released their 2Q FY20 results this morning, with organic revenue growth of +4.1%, a +20bps adjusted operating margin expansion and +7.4% adjusted EPS growth. During the call, the management team gave an early view on 2020, raising growth at three of their largest divisions. More disappointing was the Diabetes segment guidance of low single-digit growth representing a 500bps cut to sales growth (now 1-3%) as competitive pressure intensifies in the US. On the positive side, they are expecting their new pacemaker to be approved in 2021. The TAVR segment performed extremely well this quarter with 20% global growth and mid-20% US growth (check this video to understand what this is: https://mendedhearts.org/video/tavr-procedure-video/ ). Medtronic’s competitor Edwards Lifesciences recently released earnings that showed similar high growth, which we find reassuring regarding this market’s potential. MDT’s CEO is set to retire and Geoffrey Martha will take on the helm of the company in April 2020. The new CEO is looking to be more aggressive in small M&A and allocating capital to higher growth segments. Overall this was a good quarter but we see limited near-term upside in the stock, waiting for new products in the pipeline to lift sales up further. Medtronic is such a well-diversified company that overall growth can be somewhat toned-down in a sector that has done well in the last years.

Updated FY20 guidance:

Organic revenue growth +/- 4% (unchanged)

Operating margin ex-FX +40bps

EPS increased to $5.57-$5.63 from $5.54-$5.60

MDT Thesis:

· Stands to benefit from secular trends (1) increased utilization from Obamacare (2) developed populations age

· Strong balance sheet and cash flows. Increased access to non-cash should allow MDT to meaningfully increase their dividend

· 6% normalized Real Cash yield provides solid total return profile over next 2-3 years

· Ownership interest aligned. Management incentivized to maximize shareholder returns – 14% 10yr average ROIC

[tag MDT]

$MDT.US

Julie S. Praline

Director, Equity Analyst

Direct: 617.226.0025

Fax: 617.523.8118

Crestwood Advisors

One Liberty Square

Suite 500

Boston, MA 02109

www.crestwoodadvisors.com

MWTIX – Q3 2019 Commentary

MWTIX – Q3 2019 Commentary

Overview:

The MetWest Total Return Bond Fund was approximately in line (slightly under) with its benchmark during the quarter, but has slightly outperformed during the year. The slight underperformance was heavily driven by the shorter duration positions during August, as well as the Treasury futures allocation. While falling rates and exceeding financial rates compared to yields created a lag for some of MWTIX’s holdings, other allocations in corporate credit brought positive returns.

Continue reading “MWTIX – Q3 2019 Commentary”

TCPNX – Q3 2019 Commentary

TCPNX – Q3 2019 Commentary

Overview:

The Touchstone Impact Bond Fund slightly outperformed its benchmark during the quarter, yet underperformed YTD. This underperformance for the year has been heavily driven by the funds allocation to mortgages, including the funds’ underweight on agency single-family MBS, which underperformed agency multi-family MBS (fund is overweight here).

Continue reading “TCPNX – Q3 2019 Commentary”